disodium;[(2R,3S,4R,5R)-3,4-dihydroxy-5-(4-imino-2-oxidopyrimidin-1-yl)oxolan-2-yl]methyl hydrogen phosphate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷酸
• 英文名称: disodium;[(2R,3S,4R,5R)-3,4-dihydroxy-5-(4-imino-2-oxidopyrimidin-1-yl)oxolan-2-yl]methyl hydrogen phosphate
• 化学式: C9H12N3Na2O8P
• 分子量: 367.16
• InChiKey: INTPYBRGLGSMRA-WFIJOQBCSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -9.7
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  181
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• METHOD FOR PRODUCING MONOMER FOR SINGLE-STRANDED NUCLEIC ACID MOLECULE
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：US20190100540A1

  公开（公告）日：2019-04-04

  A compound represented by formula (3): or an enantiomer thereof can be obtained by comprising: reacting a compound represented by formula (1): or an enantiomer thereof with 6-hydroxyhexanoic acid in a solvent in the presence of an additive such as 1-hydroxybenzotriazole and a condensing agent, and then mixing the resultant reaction mixture, water, and a base such as alkali metal hydroxide to produce a compound represented by formula (2): or an enantiomer thereof; and reacting the compound represented by formula (2) or an enantiomer thereof with 2-cyanoethyl-N,N,N′,N′-tetraisopropylphosphorodiamidite in a solvent in the presence of a coupling activator.

  通过在溶剂中添加1-羟基苯并三唑和缩合剂的存在，将由式（1）表示的化合物或其对映体与6-羟基己酸反应，然后混合产生的反应混合物、水和碱金属氢氧化物，可以获得由式（2）表示的化合物或其对映体；并且将由式（2）表示的化合物或其对映体与2-氰乙基-N，N，N'，N' -四异丙基膦酰胺在溶剂中反应，在偶联活化剂的存在下。
• MIXED LIGAND GOLD(I) COMPLEXES AS ANTI-CANCER AGENTS
  申请人：KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS

  公开号：US20170305942A1

  公开（公告）日：2017-10-26

  Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.

  Gold(I)复合物与混合配体一起作为抗癌剂。金(I)离子配位到一个二硫代氨基甲酸盐配体和一个含磷配体（例如磷化物）。还描述了包含金(I)复合物的药物组合物、合成金(I)复合物的方法以及治疗癌症的方法。
• Pharmaceutical composition for diabetic neuropathy
  申请人：Endo Kazuki

  公开号：US20050171051A1

  公开（公告）日：2005-08-04

  The present invention relates to an agent for the prophylaxis or treatment of diabetic neuropathy, which contains cytidine 5′-diphosphocholine (CDP-choline) as an active ingredient. The agent for the prophylaxis or treatment of diabetic neuropathy of the present invention is effective for neuropathy mainly caused by metabolic disturbance of carbohydrate and is also superior in safety. Neuropathy includes peripheral neuropathy and dysautonomia. CDP-choline is effective even by oral administration.

  本发明涉及一种用于预防或治疗糖尿病神经病变的药剂，其含有胞苷酸二磷酸胆碱（CDP-胆碱）作为活性成分。本发明的用于预防或治疗糖尿病神经病变的药剂对于主要由碳水化合物代谢紊乱引起的神经病变非常有效，同时也具有较高的安全性。神经病变包括周围神经病变和自主神经功能失调。CDP-胆碱即使通过口服也是有效的。
• PHARMACEUTICAL COMPOSITION FOR DIABETIC NEUROPATHY
  申请人：YAMASA CORPORATION

  公开号：EP1362593A1

  公开（公告）日：2003-11-19

  The present invention relates to an agent for the prophylaxis or treatment of diabetic neuropathy, which contains cytidine 5'-diphosphocholine (CDP-choline) as an active ingredient. The agent for the prophylaxis or treatment of diabetic neuropathy of the present invention is effective for neuropathy mainly caused by metabolic disturbance of carbohydrate and is also superior in safety. Neuropathy includes peripheral neuropathy and dysautonomia. CDP-choline is effective even by oral administration.

  本发明涉及一种预防或治疗糖尿病神经病变的制剂，其活性成分为胞苷-5'-二磷酸胆碱（CDP-胆碱）。本发明用于预防或治疗糖尿病神经病变的制剂对主要由碳水化合物代谢紊乱引起的神经病变有效，而且在安全性方面也更胜一筹。神经病变包括周围神经病变和自律神经失调。即使口服 CDP-choline 也有效。
• METHOD FOR DETERMINING POLYNUCLEOTIDE BASE SEQUENCE AND DEVICE FOR DETERMINING POLYNUCLEOTIDE BASE SEQUENCE
  申请人：Osaka University

  公开号：EP2833126A1

  公开（公告）日：2015-02-04

  A maximum current value and pulse continuation duration are measured for each of plural pulses of tunnel current arising as a polynucleotide passes through between an electrode pair, and the polynucleotide base sequence is determined based on the maximum current value and the pulse continuation duration.

  在多核苷酸通过电极对之间时产生的多个隧道电流脉冲中，对每个脉冲的最大电流值和脉冲持续时间进行测量，并根据最大电流值和脉冲持续时间确定多核苷酸碱基序列。

表征谱图